Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia

Diagnostic Microbiology and Infectious Disease

Volumn 62, Issue 1, 2008, Pages 99-101

  Bhavnani, Sujata M ^a   Forrest, Alan ^a   Hammel, Jeffrey P ^a   Drusano, George L ^a   Rubino, Christopher M ^a   Ambrose, Paul G ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Community acquired pneumonia; Quinolones; Streptococcus pneumoniae

Indexed keywords

CIPROFLOXACIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, PNEUMOCOCCAL; QUINOLONES; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 49549085266     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.04.008     Document Type: Article

References (12)

1. Ambrose P.G., Grasela D.M., Grasela T.H., Passarell J., Mayer H.B., and Pierce P.F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45 (2001) 2793-2797
2. Ambrose P.G., Anon, Owen J.S., Van Wart S., McPhee M.E., Bhavnani S.M., Piedmonte M., and Jones R.N. Use of pharmacodynamic endpoints for the treatment of acute maxillary sinusitis. Clin. Infect. Dis. 38 (2004) 1513-1520
3. Bartlett J.G., and Mundy L.M. Community-acquired pneumonia. N. Engl. J. Med. 333 (1995) 1618-1624
4. Bello A., Hollenbaugh D., Gajjar D., Christopher L., and Grasela D. Ex vivo serum protein binding of BMS-284756: impact on the unbound AUC/MIC ratio for Streptococcus pneumoniae. Abstract of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 22-25, 2001 (2001) (Abstract A-45)
5. Bhavnani S.M., and Andes D.R. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 25 (2005) 717-740
6. 24/MIC for 6 fluoroquinolones against Streptococcus pneumoniae with survival and bactericidal activity in an animal model. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17-20, 2000 (2000) (Abstract A-289)
7. Efthymiopoulos C., Bramer S.L., and Maroli A. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin. Pharmacokinet. 33 Supp 1 (1997) 1-8
8. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., and Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37 (1993) 1073-1081
9. Forrest A., Chodash S., Amantea M.A., Collins D.A., and Schentag J.J. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 40 Suppl A (1997) 45-57
10. Niederman M.S. Review of treatment guidelines for community-acquired pneumonia. Am. J. Med. 117 (2004) 51S-57S.
11. Preston S.L., Drusano G.L., Berman A.L., Fowler C.L., Chow A.T., Dornseif B., Reichi V., Natarajan J., Wong W.A., and Corrado M. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279 (1998) 125-129
12. Van Wart S., Phillips L., Ludwig E.A., Russo R., Gajjar D.A., Bello A., Ambrose P.G., Costanzo C., Grasela T.H., Echols R., and Grasela D.M. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 48 (2004) 4766-4777